FDA-approved
Bones & muscles
Teriparatide
Evidence
FDA approved
Class
Parathyroid hormone fragment (1-34)
KEY TAKEAWAY
Teriparatide is a fragment of parathyroid hormone that builds new bone. It is approved to treat osteoporosis in people at high risk of fracture.
Written by the Veylo editorial team · Updated
November 2026
What it is
A bone-building fragment of parathyroid hormone
Approved for
Osteoporosis in people at high fracture risk
Key fact
Reduced new vertebral fractures in postmenopausal women
Route
Daily injection
Evidence strength
FDA approved
Teriparatide, sold as Forteo, contains the first 34 amino acids of human parathyroid hormone.
Given in daily pulses it stimulates bone-forming cells more than bone-resorbing cells, increasing bone density.
The FDA approved teriparatide in 2002 for osteoporosis. An earlier boxed warning about osteosarcoma seen in rats was removed in 2020.
Postmenopausal osteoporosis, osteoporosis in men and glucocorticoid-induced osteoporosis.
Nausea, leg cramps, dizziness and raised calcium levels can occur. Treatment is generally limited to about two years.
Neer RM et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.